BiotechTube

Acalabrutinib + Lenalidomide + Rituximab + Obinutuzumab

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mantle Cell Lymphoma

Conditions

Mantle Cell Lymphoma

Trial Timeline

Oct 11, 2019 → Sep 1, 2027

NCT ID
NCT03863184

About Acalabrutinib + Lenalidomide + Rituximab + Obinutuzumab

Acalabrutinib + Lenalidomide + Rituximab + Obinutuzumab is a phase 2 stage product being developed by AstraZeneca for Mantle Cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT03863184. Target conditions include Mantle Cell Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03863184Phase 2Active

Competing Products

20 competing products in Mantle Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
52
Obinutuzumab + Glofitamab + PirtobrutinibEli LillyPhase 2
52
enzastaurinEli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
77
Pirtobrutinib + Rituximab + VenetoclaxEli LillyPhase 2
52
Pirtobrutinib and rituximabEli LillyPhase 2
52
gemcitabine + mitoxantrone + rituximabEli LillyPhase 2
52
Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
77
VenetoclaxAbbViePhase 2
52
Ibrutinib + VenetoclaxAbbViePhase 2
52
ABT-199 and Ibrutinib CombinationAbbViePhase 1
33
Venetoclax Oral Tablet [Venclexta]AbbViePhase 2
52
Acalabrutinib capsuleAstraZenecaApproved
85
Acalabrutinib in combination with BR + Acalabrutinib in combination with VRAstraZenecaPhase 1
33
Acalabrutinib + Venetoclax + ObinutuzumabAstraZenecaPhase 1/2
41
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapyAstraZenecaPhase 2
52
Acalabrutinib + Venetoclax + RituximabAstraZenecaPhase 2
52
Acalabrutinib + RituximabAstraZenecaPhase 2
52
Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment DAstraZenecaPhase 1
33

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85